Clinical Trial Update: Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4 [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating immunogenicity and safety of combined immunization with a Beijing-produced COVID-19 vaccine and PPV23/IIV4; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonia Pneumococcal

Drugs mentioned

• COVID-19 Vaccine (Produced in Beijing)
• IIV4 (inactivated influenza vaccine for quadrivalent formulation)
• PPV23 (pneumococcal polysaccharide vaccine)

Snippet

Sponsor: China National Biotec Group Company Limited | Conditions: Influenza, Human, Pneumonia, Pneumococcal | Phase 4 | Status: COMPLETED